NCT05683418
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 19 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Trial sites expanded: 18 → 25 locations
Notable Primary and study completion dates: Dec 2026 to Dec 2027v18 Show 7 more changesShow less
- Eligibility criteria shortened, about 87 words
- Interventions: TOS-358 (Drug) to Fulvestrant (Drug), Palbociclib (Drug), Ribociclib (Drug), TOS-358 (Drug)
- Secondary endpoints expanded, about 6 words
- Study sites revised (18)
- Study arms: 1 to 3
- Study description shortened, about 3 words
- Study title shortened, about 4 words
Notable Primary and study completion dates: Dec 2025 to Dec 2026v17 Show 4 more changesShow less
- Eligibility criteria shortened, about 76 words
- Study sites: 19 to 18
- Study description shortened, about 23 words
- Study title expanded, about 5 words
- Minor Study sites: 20 to 19v16
- Minor Study sites: 11 to 20v15
Show 13 earlier versionsHide 13 earlier versions
- Notable Eligibility criteria expanded, about 4 words
- Study description shortened, about 13 words
- Site contacts updated at 11 of 11 sites
- Minor Study sites: 16 to 11v13
- Minor Study sites: 12 to 16v12
- Minor Study sites: 11 to 12v11
- Minor Site contacts updated at 1 of 11 sitesv10
- Minor Study sites: 10 to 11v9
- Minor Study sites: 8 to 10v8
- Minor Study sites: 7 to 8v7
- Minor Study sites: 5 to 7v6
- Minor Study sites: 4 to 5v5
- Minor Study sites: 2 to 4v4
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Feb 2023 to Feb 15, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Determine the rate of dose-limiting toxicities (DLTs)
Timeframe: First 21 days of treatment
Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5
Timeframe: Start of treatment to 30 days after last dose
Secondary (1)
ORR and duration of tumor control
Arms and interventions
TOS-358 + fulvestrantExperimental
TOS-358 + fulvestrant at standard dosing
TOS-358 + fulvestrant + CDK4/6iExperimental
TOS-358 + fulvestrant + CDK4/6i
TOS-358Experimental
PIK3CA covalent inhibitor
Drugs: TOS-358, Fulvestrant, Palbociclib, Ribociclib
Sites
25 sites in 2 countries
United States 16, Spain 9